Introduction

Tagra Biotechnologies Ltd. ("Tagra") has adopted and applies a zero-tolerance policy against all forms of bribery and corruption. The commitment to doing business with integrity is one of the pillars of Tagra's Code of Ethics.

Definitions

Bribery is the offering, promising, giving, accepting, or soliciting of an advantage as an inducement for an action that is illegal or a breach of trust.

A bribe is an inducement or reward offered, promised, or provided to gain any commercial, contractual, regulatory, or personal advantage.

Principles

• Tagra's anti-corruption policy applies company-wide to all employees.

• Tagra's employees must not engage in any form of bribery, either directly or through any third party (such as an agent or distributor).

• We prohibit "facilitation payments", which consist of the payment of small amounts, directly or indirectly, to a government official or any other third party (including from the private sector) to influence official or business action or otherwise obtain an improper advantage.

• We do not make donations, whether in cash or kind, in support of any political parties or candidates, as this can be perceived as an attempt to gain an improper business advantage.

• We forbid gifts and entertainment, either given or received, that might influence or be perceived as influencing a business relationship.

Reporting

Incidences of suspected corruption must be reported immediately to Tagra's Chief Financial Officer.

Tagra's employees must report if they are offered a bribe by a third party, are asked to make one, suspect that this may happen in the future, or believe that they are victims of another form of unlawful activity.

Tagra's whistleblower policy provides an alternative reporting mechanism and protective arrangements to encourage Tagra's employees to speak up about possible wrongdoing for early resolution.

Tagra's employees who refuse to accept or offer a bribe, or those who raise concerns or report another's wrongdoing, are sometimes worried about possible repercussions. We aim to encourage openness and will support anyone who raises genuine concerns in good faith under this policy, even if they turn out to be mistaken.

Ronen Roshkin, CFO. October 2025.